Duravant to Acquire Pattyn, Provider of Packaging Automation Systems for Bulk and Industrial Applications
7.2.2025 15:00:00 CET | Business Wire | Press release
Automation solutions leader Duravant has signed a definitive agreement to acquire Pattyn.
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced today that it has entered into a definitive agreement to acquire the Pattyn Group BV (‘Pattyn”), a designer and manufacturer of automation systems specializing in B2B packaging. Pattyn is recognized as the premier leader for delivering comprehensive automation solutions and value-added services for bag-in-box packaging applications. Headquartered in Bruges, Belgium, Pattyn has over 70 years of expertise in machinery design and turnkey systems for counting, weighing, filling, and packing technologies for food, ingredients, and various non-food sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207117623/en/
“We are extremely excited to partner with Pattyn,” said Mike Kachmer, Chairman and CEO of Duravant. “Pattyn has a rich history delivering high quality solutions to a global customer base in over 80 countries. Their impressive growth is attributed to their unwavering focus on customer satisfaction and building lasting relationships, which aligns perfectly with Duravant’s dedication to ensuring customer success.”
Pattyn operates out of six specialized manufacturing sites in Belgium, France and Spain and has sales and service divisions in North America and Asia. Founded by Jean Pattyn in 1952 and expanded through the vision of Paul Pattyn in 1976, the company grew from a local business to a worldwide supplier of packaging automation. Pattyn’s third generation owners and shareholders Stan Pattyn and Lynn Pattyn, alongside Pattyn COO Benjamin de Chilly, further led the company’s transformation with continuous innovation and development of new packaging technologies, digital offerings, and a service-minded approach from design to installation and complete aftermarket support.
“Pattyn has had a strong track record of solid performance, and we know that our potential to grow faster will happen alongside a strong partner,” said Stan Pattyn. “Through further investments in product development, operational excellence, and emerging market expansion, we will not only continue to thrive, but we will be empowered to better serve our customers and partners around the globe. Duravant is the perfect partner for the Pattyn Group and our employees.”
“We are thrilled to join forces with Duravant and collaborate with their family of world-class brands,” said Lynn Pattyn. “Duravant has a leading position across a wide array of end markets, from food & beverage to consumer goods, agriculture and industrial goods, to logistics and e-commerce. Pattyn’s opportunity to expand into new end markets with Duravant is core to our growth vision. But what’s most exciting is that Duravant’s customer-centric culture aligns perfectly with Pattyn’s commitment to delivering an excellent customer experience. We share that same DNA.”
Benjamin de Chilly adds, “Duravant is a true global organization with deep roots in Europe. They have a strong manufacturing footprint on the continent with renowned automation equipment brands such as Mespack, Votech, Marelec, Foodmate, Henneken, Multiscan, FMH Conveyors and Motion06. They recently invested in emerging markets Brazil, Mexico, China and Thailand where they established local sales, parts and service infrastructure to enhance their ability to serve customers in those regions.”
Pattyn represents a strategic acquisition for Duravant, expanding the company’s packaging machinery portfolio with innovative engineered solutions. Pattyn’s advanced automation technologies provide custom solutions through modular system designs while their equipment and consumables meet the highest food safety standards. Pattyn’s strong solution set for bakery applications further deepens Duravant’s relationships with customers in this sector.
The transaction, which remains subject to customary regulatory approvals, is expected to close in the second quarter of 2025. Following the close of the transaction, Pattyn will be a distinct Operating Company within Duravant’s Packaging Solutions Group. The current Pattyn Group management team will continue to oversee operations after the completion of the sale, and Pattyn’s 550 employees will join Duravant’s 3600 employees around the globe.
About Duravant
Headquartered in Downers Grove, IL, Duravant is a global engineered equipment company with manufacturing, sales and service facilities throughout North America, South America, Europe and Asia. Through their portfolio of operating companies, Duravant delivers trusted end-to-end automation solutions for customers and partners through engineering and integration expertise, project management and operational excellence. With worldwide sales distribution and support through the Duravant Lifecycle Services network, they provide immediate and lifetime aftermarket support to all the markets they serve in the protein processing, food sorting and handling, packaging, and material handling sectors. Duravant’s market-leading brands are synonymous with innovation, durability and reliability. For more information, visit www.duravant.com.
About Pattyn
Headquartered in Bruges, Belgium, Pattyn Group is a manufacturer and service provider of innovative and highly engineered packaging automation equipment specializing in modular solutions for counting, weighing, filling and bag-in-a-box applications. Since 1952, the company serves the B2B packaging segment and a diverse customer base that includes food and non-food producers in over 80 countries worldwide. Committed to fostering lifetime partnerships, Pattyn designs and delivers turnkey packaging lines with innovative modular designs that deliver custom solutions. The company provides aftermarket support with consumables, parts and comprehensive service programs. With 6 manufacturing sites in Belgium, France and Spain, and sales and service hubs in the United States and Asia, Pattyn partners with their customers to improve the efficiency, performance and quality of their industrial packaging needs. For more information, visit www.pattyn.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207117623/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom